Yatharth Hospitals appoints Ashutosh Kumar Jha as Group Chief of Strategy and M&A

Yatharth Hospital and Trauma Care Services, a prominent private super specialty hospital in North India, recently appointed Ashutosh Kumar Jha as Group Chief – Strategy, Mergers & Acquisitions (M&A), and Investor Relations. This strategic move reflects the hospital’s dedication to expanding its M&A activities and enhancing stakeholder engagement in the healthcare sector.

With almost twenty years of experience in the healthcare field, Ashutosh brings a wealth of knowledge to his new role. Before joining Yatharth Hospitals, he held key positions at Artemis Hospital as Chief – Strategy, M&A, Investor Relations and Organization Growth, and at Max Healthcare as Director and Head – Growth and M&A.

Ashutosh has been instrumental in driving both organic and inorganic growth initiatives, managing stakeholder relationships, and overseeing strategic projects. His background includes significant roles at Global Growth Holdings, Bosch Group, and Maruti Suzuki, with expertise in private equity, capital markets, investor relations, fundraising, corporate finance, and M&A.

In his capacity at Yatharth Hospitals, Ashutosh will be responsible for shaping and implementing strategic plans, leading M&A efforts, and nurturing relationships with investors and strategic partners. These responsibilities are crucial for driving the expansion and innovation of Yatharth Hospitals’ healthcare services.

Industry experts Vaios Barlas, Global Director Healthcare at Clariant, and Bhushan Thekedar, Head of Global Business Development Healthcare at Clariant, emphasize the importance of India in their ecosystem. Dr. R. Ananthanarayanan, CEO of Sajjan India, estimates a capital expenditure commitment in the range of Rs. 200-300 Cr. Dr. Aman Desai, Promoter and Whole Time Director of Aether Industries, highlights the company’s focus on organic expansion and building their plants.

Several key appointments have been made in the pharmaceutical industry, including Payal Agrawaal as MD – India & South Asia at PerkinElmer, Kirti Ganorkar as the Managing Director at Sun Pharma, and Prabhakaran Balakrishnan Nair as Global Chief Manufacturing Officer at Cipla.

In terms of recent developments, Faron has published a study on the role of sClever-1 as an immune blocker in cancer treatment, atai and Beckley Psytech have announced positive Phase 2b results for treatment-resistant depression, and argenx is progressing clinical development of agonist antibody for myasthenic syndromes.

Yatharth Hospitals’ appointment of Ashutosh Kumar Jha as Group Chief – Strategy, M&A, and Investor Relations signals a strategic focus on expansion and stakeholder engagement within the healthcare sector. This move reflects the hospital’s commitment to growth and innovation in delivering healthcare services to its patients.